Clinical symptoms of SARS-CoV-2 breakthrough infection during the Omicron period in relation to baseline immune status and booster vaccination-A prospective multicentre cohort of health professionals (SURPRISE study).
Covid‐19
breakthrough infection
health professionals
symptoms
vaccine
Journal
Influenza and other respiratory viruses
ISSN: 1750-2659
Titre abrégé: Influenza Other Respir Viruses
Pays: England
ID NLM: 101304007
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
received:
25
11
2022
revised:
22
05
2023
accepted:
30
05
2023
medline:
26
6
2023
pubmed:
22
6
2023
entrez:
22
6
2023
Statut:
epublish
Résumé
The effects of different types of pre-existing immunity on the frequency of clinical symptoms caused by the SARS-CoV-2 breakthrough infection were prospectively assessed in healthcare workers during the Omicron period. Among 518 participants, hybrid immunity was associated with symptom reduction for dizziness, muscle or limb pain and headache as compared to vaccination only. Moreover, the frequencies of dizziness, cough and muscle or limb pain were lower in participants who had received a booster vaccine dose. Thus, hybrid immunity appeared to be superior in preventing specific symptoms during breakthrough infection compared to vaccination alone. A booster vaccine dose conferred additional symptom reduction.
Identifiants
pubmed: 37346094
doi: 10.1111/irv.13167
pii: IRV13167
pmc: PMC10279996
doi:
Substances chimiques
Vaccines
0
Types de publication
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13167Informations de copyright
© 2023 The Authors. Influenza and Other Respiratory Viruses published by John Wiley & Sons Ltd.
Déclaration de conflit d'intérêts
No conflict of interest was declared.
Références
Euro Surveill. 2022 Apr;27(16):
pubmed: 35451363
Clin Microbiol Infect. 2021 Sep;27(9):1336-1344
pubmed: 34020033
N Engl J Med. 2022 Apr 21;386(16):1532-1546
pubmed: 35249272
BMC Med. 2021 Oct 14;19(1):270
pubmed: 34649585
PLoS Med. 2022 Nov 7;19(11):e1004125
pubmed: 36342956
Lancet Infect Dis. 2023 Apr;23(4):435-444
pubmed: 36436536
Clin Infect Dis. 2022 Aug 24;75(1):e1011-e1019
pubmed: 35090015
N Engl J Med. 2022 Jul 7;387(1):21-34
pubmed: 35704396
Lancet Infect Dis. 2022 Jul;22(7):945-946
pubmed: 35588753
J Clin Microbiol. 2022 Jun 15;60(6):e0048221
pubmed: 35249377